Press Release Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China 16 hours ago
Press Release Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Aug 6
Press Release Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 Jul 30